tbuckley/cabot-search huggingface dataset:
Nedd9 Over-Expression Leads to Imatinib Resistance in Gastrointestinal Stromal Tumor Cells.
Authors: Thao Le Ba, Vu Hoang Anh, Shigeki Taniguchi, Kazuki Yasuda, Fumiharu Yagasaki, Takahiro Taguchi, Toshiki Watanabe, Yuko Sato
Journal: Blood (2007)
Comparison of Outcomes Between Transplantation From Unrelated Donor Umbilical Cord Blood and From Unrelated Donor Bone Marrow or Peripheral Blood in Children with Acute Leukemia.
Authors: Soo Hyun Lee, Heewon Chueh, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo
Journal: Blood (2009)
STUDIES ON TYPHUS FEVER
Authors: Hans Zinsser, M. Ruiz Castaneda
Journal: The Journal of Experimental Medicine (1930)

We have adduced strong evidence in favor of identifying the virus of Mexican typhus fever with the Rickettsiae, or Mooser bodies, observed in the tunica lesions of Mexican typhus guinea pigs. Were it not for the possible presence of a few remaining cell fragments in the washings we would consider this evidence crucial proof.
A phase I clinical trial demonstrates that nfP2X<sub>7</sub> -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma
Authors: S.M. Gilbert, A. Gidley Baird, S. Glazer, J.A. Barden, A. Glazer, L.C. Teh, J. King
Journal: British Journal of Dermatology (2017)

Expression of P2X7, an ATP‐gated calcium channel, increases cancer cell proliferation and invasiveness. A variant of P2X7 (termed nfP2X7), in which a normally hidden epitope (E200) is exposed for antibody binding, is observed in a variety of different cancers. To investigate the safety, tolerability and pharmacokinetics and assess indicative efficacy of a novel antibody ointment as a therapeutic for basal cell carcinoma (BCC). An open‐label, phase I clinical trial was undertaken at three dermatology clinics to evaluate the safety and tolerability of topical administration of an ointment containing 10% sheep polyclonal anti‐nfP2X7 antibodies (BIL010t) to primary BCC lesions twice daily for 28 days. Twenty‐one patients with primary BCC lesions at least 0·5 cm2 in area and less than 2·0 cm in diameter were enrolled. The primary end points were safety, tolerability and pharmacokinetics. Change in lesion size after treatment was determined and histology was performed on pretreatment and end‐of‐treatment (EOT) biopsies. Compliance was very high, with treatment being well tolerated. The most common adverse events were treatment site erythema, pruritus, dryness and pain. There was no evidence of systemic penetration of the sheep antibody. Lesions were measured prior to and after 28 days of treatment, with 65% of patients showing a reduction in lesion area, 20% showing no change and 15% showing an increase. Histopathology of post‐treatment excision of lesion sites showed eight patients with stable disease, nine with partial response and three with complete response. Antibodies against nfP2X7 (BIL010t) provide a novel, safe and well‐tolerated treatment for BCC.
Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
Authors: Andrea Pellagatti, Eva Hellström-Lindberg, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo Della Porta, Martin Jädersten, Sally Killick, Davendra P. Sohal, Amit Verma, Mario Cazzola, James S. Wainscoat, Jacqueline Boultwood
Journal: Blood (2008)
Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis
Authors: B. T. Teh, X. J. Yang, M. Tan, H. L. Kim, W. Stadler, N. G. Vogelzang, R. Amato, R. Figlin, A. Belldegrun, C. G. Rogers
Journal: Journal of Clinical Oncology (2006)

4503 Background: Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphological classification of PRCC into Type 1 and Type 2 tumors has been recently proposed, but its biological relevance remains uncertain. Methods: We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analysis. Comparative genomic microarray analysis (CGMA) was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples, with 15 independent tumors. Results: We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histological subtypes: Type 1, low-grade Type 2 and mixed Type 1/low-grade Type 2 tumors. The second class, with poor survival, corresponded to high-grade Type 2 tumors (n = 11). Dysregulation of G1/S and G2/M checkpoint genes were found in Class 1 and Class 2 tumors respectively, alongside characteristic chromosomal aberrations. We identified a 7-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in Class 1 tumors, and of topoisomerase IIα in Class 2 tumors. Conclusions: We report two molecular subclasses of PRCC, which are biologically and clinically distinct, which may be readily distinguished in a clinical setting. This may also have therapeutic implications. No significant financial relationships to disclose.
Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Authors: Rakhee Vaidya, Domenica Caramazza, Christy Finke, Terra Lasho, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2010)
Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma
Authors: Aleksandr Lazaryan, Rachid Baz, Mohamad A Hussein, Paul Elson, Beth Faiman, Becky Habecker, Mary Ann Karam, Janice Reed, Kimberly Hamilton, Kellie Bruening, Gordan Srkalovic, Steven Andresen, Matt Kalaycio, John William Sweetenham, Ronald Sobecks, Robert Dean, Robert Knight, Jerome B. Zeldis, Frederic J. Reu
Journal: Blood (2010)
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Charlotte K.Y. Ng, Salvatore Piscuoglio, Felipe C. Geyer, Kathleen A. Burke, Fresia Pareja, Carey A. Eberle, Raymond S. Lim, Rachael Natrajan, Nadeem Riaz, Odette Mariani, Larry Norton, Anne Vincent-Salomon, Y. Hannah Wen, Britta Weigelt, Jorge S. Reis-Filho
Journal: Clinical Cancer Research (2017)

Purpose: Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic type of breast cancer, predominantly of triple-negative phenotype, and characterized by the presence of malignant cells showing squamous and/or mesenchymal differentiation. We sought to define the repertoire of somatic genetic alterations and the mutational signatures of MBCs.Experimental Design: Whole-exome sequencing was performed in 35 MBCs, with 16, 10, and 9 classified as harboring chondroid, spindle, and squamous metaplasia as the predominant metaplastic component. The genomic landscape of MBCs was compared with that of triple-negative invasive ductal carcinomas of no special type (IDC-NST) from The Cancer Genome Atlas. Wnt and PI3K/AKT/mTOR pathway activity was assessed using a qPCR assay.Results: MBCs harbored complex genomes with frequent TP53 (69%) mutations. In contrast to triple-negative IDC-NSTs, MBCs more frequently harbored mutations in PIK3CA (29%), PIK3R1 (11%), ARID1A (11%), FAT1 (11%), and PTEN (11%). PIK3CA mutations were not found in MBCs with chondroid metaplasia. Compared with triple-negative IDC-NSTs, MBCs significantly more frequently harbored mutations in PI3K/AKT/mTOR pathway-related (57% vs. 22%) and canonical Wnt pathway-related (51% vs. 28%) genes. MBCs with somatic mutations in PI3K/AKT/mTOR or Wnt pathway-related genes displayed increased activity of the respective pathway.Conclusions: MBCs are genetically complex and heterogeneous, and are driven by a repertoire of somatic mutations distinct from that of triple-negative IDC-NSTs. Our study highlights the genetic basis and the importance of PI3K/AKT/mTOR and Wnt pathway dysregulation in MBCs and provides a rationale for the metaplastic phenotype and the reported responses to PI3K/AKT/mTOR inhibitors in these tumors. Clin Cancer Res; 23(14); 3859-70. ©2017 AACR.
QOL-26DESCRIBING SYMPTOM BURDEN IN PATIENTS WITH LEPTOMENINGEAL METASTASES: SELECTING AN INSTRUMENT
Authors: Julie Walker, Ivo Tremont, Barbara O'Brien, Terri Armstrong
Journal: Neuro-Oncology (2015)

BACKGROUND: Patients with leptomeningeal metastases (LM) have disease burden involving the membranes surrounding the brain, spinal cord or both, and a short disease trajectory. Limited studies have explored presenting symptoms and the relationship to functional status. The objectives of this study are to evaluate the utility of the MD Anderson Symptom Inventory-brain tumor (MDASI-BT) and the MDASI-spine tumor (MDASI-SP) symptom report instruments in capturing presenting symptoms in this population, and to describe functional status (Karnofsky Performance Score [KPS]) in relation to endorsed symptoms and tumor location. METHODS: Clinical records of 45 patients with LM were reviewed for presenting symptoms. Endorsed symptoms were recorded using the MDASI-BT and MDASI-SP. Both instruments were modified to capture dichotomous data (present/not present). Additional demographic and clinical data were collected (age, gender, tumor location, and KPS). Frequency analysis was used to describe symptom occurrence and KPS. Two-way analysis of variance (ANOVA) was performed to explore differences in KPS for tumor location, and endorsed symptoms. RESULTS: The subjects were primarily female (80%), with a median age of 51 years. The most common location of LM was the brain (42.2%) followed by both brain and spine involvement (37.8%). Twenty-one (46.7%) endorsed symptoms corresponding to both the MDASI-BT and the MDASI-SP. Of those endorsing symptoms corresponding with only one instrument, a greater number of patients reported symptoms corresponding with the MDASI-BT (31%). Pain was the most frequently reported presenting symptom (33%), followed by numbness/tingling (31%). KPS at diagnosis ranged from 50% to 100% (median = 80%). Using ANOVA there was no significant difference in KPS for tumor location and endorsed symptoms. CONCLUSIONS: These findings indicate that, based on frequency analysis, the MDASI-BT shows slightly greater utility in capturing symptoms in LM patients at presentation. KPS was not associated with endorsed symptoms or tumor location at presentation of LM.
Workshops of the Sixth International Brain–Computer Interface Meeting: brain–computer interfaces past, present, and future
Authors: Jane E. Huggins, Christoph Guger, Mounia Ziat, Thorsten O. Zander, Denise Taylor, Michael Tangermann, Aureli Soria-Frisch, John Simeral, Reinhold Scherer, Rüdiger Rupp, Giulio Ruffini, Douglas K. R. Robinson, Nick F. Ramsey, Anton Nijholt, Gernot Müller-Putz, Dennis J. McFarland, Donatella Mattia, Brent J. Lance, Pieter-Jan Kindermans, Iñaki Iturrate, Christian Herff, Disha Gupta, An H. Do, Jennifer L. Collinger, Ricardo Chavarriaga, Steven M. Chase, Martin G. Bleichner, Aaron Batista, Charles W. Anderson, Erik J. Aarnoutse
Journal: Brain-Computer Interfaces (2017)

The Sixth International Brain–Computer Interface (BCI) Meeting was held 30 May–3 June 2016 at the Asilomar Conference Grounds, Pacific Grove, California, USA. The conference included 28 workshops covering topics in BCI and brain–machine interface research. Topics included BCI for specific populations or applications, advancing BCI research through use of specific signals or technological advances, and translational and commercial issues to bring both implanted and non-invasive BCIs to market. BCI research is growing and expanding in the breadth of its applications, the depth of knowledge it can produce, and the practical benefit it can provide both for those with physical impairments and the general public. Here we provide summaries of each workshop, illustrating the breadth and depth of BCI research and highlighting important issues and calls for action to support future research and development.
SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.
Authors: Yves Bertrand, Anne Auvrignon, Brigitte Nelken, Valérie Mialoux, Francoise Mechinaud, Catherine Patte, Dominique Plantaz, Nathalie Le Guyader, Marisol Urbieta, Yves Perel, Andre Baruchel9, Guy Leverger
Journal: Blood (2005)
A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms
Authors: Huyen Tran, Jamie P Nourse, Rod Lea, Timothy A. Brighton, Andrew Grigg, Simon McRae, Daniel Thurley, Maher Gandhi, John Catalano
Journal: Blood (2011)
Flow Cytometry Quantification of Leukemic Stem Cells Is Associated with Risk Stratification and May Be Useful for Minimal Residual Disease in Acute Myeloid Leukemia
Authors: Lorena Lobo Figueiredo Pontes, Leandro F. Dalmazzo, Luciana Correa Oliveira de Oliveira, Bárbara A Santana-Lemos, Felipe M Furtado, Antonio R Lucena-Araujo, Mariana Tereza Lira Benício, Fabio Morato Oliveira, Ana Silvia G de Lima, Aglair Bergamo Garcia, Roberto P. Falcao, Eduardo M. Rego
Journal: Blood (2011)
Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency
Authors: M. Cem Ar, Serdar Sahin, Sevil Sadri, Isil Erdogan, Ayse Salihoglu, Tugrul Elverdi, Fevzi Firat Yalniz, Ahmet Emre Eskazan, Seniz Ongoren, Teoman Soysal, Yildiz Aydin, Zafer Baslar
Journal: Blood (2015)
Balloon enteroscopy-assisted biliary drainage using a diathermic dilator followed by placement of a novel ultra-slim metallic stent
Authors: Hiroshi Kawakami, Yoshimasa Kubota, Shinya Ashizuka, Masaru Haraguchi, Ichiro Sannomiya
Journal: Endoscopy (2017)

Endoscopic management of malignant biliary stricture after hepaticojejunostomy is challenging. Although balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (ERCP) has been developed, dedicated devices are still insufficient. We present a case of successful enteroscopic dilation using a wire-guided diathermic dilator [1] [2] [3] [4] [5], and placement of a novel, ultra-slim, uncovered, self-expandable, metallic stent (USEMS) for the treatment of a severe malignant stricture of the perihilar bile duct after hepaticojejunostomy.
Association between continuity of care in general practice and hospital admissions for ambulatory care sensitive conditions: cross sectional study of routinely collected, person level data
Authors: Isaac Barker, Adam Steventon, Sarah R Deeny
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To assess whether continuity of care with a general practitioner is associated with hospital admissions for ambulatory care sensitive conditions for older patients. <b>Design</b>&nbsp;Cross sectional study. <b>Setting</b>&nbsp;Linked primary and secondary care records from 200 general practices participating in the Clinical Practice Research Datalink in England. <b>Participants</b>&nbsp;230 472 patients aged between 62 and 82 years and who experienced at least two contacts with a general practitioner between April 2011 and March 2013. <b>Main outcome measure</b>&nbsp;Number of hospital admissions for ambulatory care sensitive conditions (those considered manageable in primary care) per patient between April 2011 and March 2013. <b>Results</b>&nbsp;We assessed continuity of care using the usual provider of care index, which we defined as the proportion of contacts occurring between April 2011 and March 2013 that were with the most frequently seen general practitioner. On average, the usual provider of care index score was 0.61. Continuity of care was lower among practices with more doctors (average score 0.59 in large practices versus 0.70 in small practices). Higher continuity of care was associated with fewer admissions for ambulatory care sensitive conditions. When modelled, controlling for demographic and clinical patient characteristics, an increase in the usual provider of care index of 0.2 for all patients would reduce these admissions by 6.22% (95% confidence interval 4.87% to 7.55%). There was greater evidence for an association among patients who were heavy users of primary care. Heavy users also experienced more admissions for ambulatory care sensitive conditions than other patients (0.36 admissions per patient for those with ≥18 contacts with a general practitioner, compared with 0.04 admissions per patient for those with 2-4 contacts). <b>Conclusions</b>&nbsp;Strategies that improve the continuity of care in general practice may reduce secondary care costs, particularly for the heaviest users of healthcare. Promoting continuity might also improve the experience of patients and those working in general practice.
The Clonal Inventory of Gene Corrected Hematopoiesis in Three Successful Clinical Gene Therapy Trials
Authors: Kerstin Schwarzwaelder, Manfred Schmidt, Annette Deichmann, Steven J. Howe, Marion G. Ott, Stefan Stein, Ulrich Siler, Salima Hacein-Bey-Abina, Hanno Glimm, Dieter Hoelzer, Marina Cavazzana-Calvo, Adrian J. Thrasher, Reinhard Seger, Manuel Grez, Christof von Kalle
Journal: Blood (2007)
A Pilot Phase II Study of C-MOPP-R, Ibritumomab Tiuxetan, and Autologous Transplant for Untreated and Relapsed Follicular Lymphoma: Response, Toxicity, and Feasibility,
Authors: Mark J. Fesler, Yashaswini Yeragunta, Sheetal A. Majethia, Paul J. Petruska
Journal: Blood (2011)
STP plans to cut GP numbers are “alarming,” says royal college
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Plans to reduce the number of GPs in parts of England are “alarming” and contradict promises to invest more in primary care, the Royal College of General Practitioners has said.

In a new report,1 the college said that proposals outlined in some sustainability and transformation plans (STPs) to reduce or not expand on the number of GPs should be blocked by NHS England, as they run contrary to pledges to invest in general practice and move more services into the community.

The report, which assessed progress in delivering pledges made in NHS England’s GP Forward View ,2 …
Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma
Authors: Georg Lenz, George Wright, Sandeep Dave, Wenming Xiao, John Powell, Hong Zhao, Weihong Xu, Bruce Tan, Neta Goldschmidt, Javeed Iqbal, Julie Vose, Martin A Bast, Kai Fu, Dennis D. Weisenburger, Timothy C. Greiner, James O. Armitage, Alastair Kyle, Lorraine May, Randy D. Gascoyne, Joseph M. Connors, Gunhild Troen, Harald Holte, Stein Kvaloy, Daan Dierickx, Gregor Verhoef, Jan Delabie, Erlend B. Smeland, Pedro Jares, Antonio Martinez, Armando Lopez-Guillermo, Emili Montserrat, Elias Campo, Rita M. Braziel, Thomas P. Miller, Lisa M. Rimsza, James R. Cook, Brad Pohlman, John William Sweetenham, Raymond R. Tubbs, Richard I. Fisher, Elena Hartmann, Andreas Rosenwald, German Ott, Hans- Konrad Muller-Hermelink, David Wrench, T. Andrew Lister, Elaine S. Jaffe, Wyndham Wilson, Wing C. Chan, Louis M. Staudt
Journal: Blood (2008)
Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease
Authors: Samantha Pozzi, Hua Yan, Sonia Vallet, Nileshwari Vaghela, Mariateresa Fulciniti, Diana Cirstea, Loredana Santo, Siddhartha Mukherjee, Teru Hideshima, Linda Schirtzinger, Stuart Kuhstoss, Nikhil C. Munshi, Kenneth C Anderson, David Scadden, Noopur Raje
Journal: Blood (2008)
Surveillance for dysplasia in inflammatory bowel disease: it is time to move forward
Authors: Hazem Hammad, Tonya Kaltenbach, Roy Soetikno
Journal: Endoscopy (2017)

The decision of whether or not to use chromoendoscopy with targeted biopsy (CETB) to detect dysplasia in patients with inflammatory bowel disease (IBD) ought to follow the principle of rational decision-making. But many, including key opinion leaders, are still on the fence.
Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.
Authors: Theis H. Terwey, Gero Massenkeil, Ingo Tamm, Christoph Lutz, Philipp Hemmati, Stefan Neuburger, Bernd Dorken, Renate Arnold
Journal: Blood (2006)
Epigenetics of Cellular Memory: Insights from the Chromatin Accessibility Landscape of the Mitotic Genome
Authors: Chris C.S. Hsiung, Christapher Morrissey, Maheshi Udugama, Christopher Frank, Cheryl A. Keller, Songjoon Baek, Belinda Giardine, Gregory E. Crawford, Myong-Hee Sung, Arjun Raj, Ross C Hardison, Gerd A. Blobel
Journal: Blood (2014)
Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib.
Authors: Khaled B. Ali, Shetal N. Shah, Laura S. Wood, Jorge A. Garcia, Robert Dreicer, Timothy D. Gilligan, Brian I. Rini
Journal: Journal of Clinical Oncology (2012)

420 Background: The determination of progressive disease (PD) on sunitinib in mRCC by conventional tumor size criteria is often complex. Frequently, radiology reports cite disease progression that does not meet RECIST criteria or does not adequately describe index lesions. Characterization of the frequency and magnitude of this phenomenon has not been previously reported. Methods: The medical records of a subset of mRCC patients treated at The Cleveland Clinic who had received sunitinib for &gt; 12 months were retrospectively reviewed. All Radiology reports from post-baseline scans were reviewed for the presence of text in the body or conclusion of the report consistent with disease progression (specifically the terms ‘progressive’, ‘new’ and/or ‘interval enlargement/worsening’). The date of the report first containing one or more of these terms was recorded, as was the date of RECIST-defined PD determined by the treating Oncologist. Results: Twenty patients were identified in an initial review. Patient characteristics included: 85% male, 100% clear cell histology, 90% prior nephrectomy and 80% with prior systemic therapy. Thirteen patients (65%) had a radiology report citing a progressive disease term prior to treating physician-determined RECIST-defined PD. The median time from first radiology report citing a progressive disease term until RECIST PD per Oncologist measurements was 2.9 months (range, 0 to 12.8 months). Conclusions: There is significant discrepancy between the first mention of disease progression by a Radiology report and when a treating Oncologist measures disease progression per RECIST criteria. This discrepancy could impact patient care by influencing drug discontinuation. These data emphasize the importance of multidisciplinary scan review and tumor measurements by both radiologists and treating physicians. Analysis is ongoing in additional patients.
Double-Blind, Placebo-Controlled, Randomized Clinical Trial of the Effect of the Dietary Supplement S-Adenosyl-L-Methionine (AdoMet) on Plasma Homocysteine (Hcy) Levels in Healthy Human Subjects.
Authors: Michael A. Thompson, Brent A. Bauer, Laura L. Loehrer, Stephen S. Cha, Jayawant N. Mandrekar, Amit Sood, Dietland L. Wahner-Roedler
Journal: Blood (2006)
Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients
Authors: Tasha Lin, Hassan B Alkhateeb, Aref Al-Kali, Michelle Ann Elliott, Naseema Gangat, William J Hogan, Grzegorz S. Nowakowski, Carrie A. Thompson, Thomas E. Witzig, Stephen M. Ansell, Mark R Litzow, Mrinal M Patnaik
Journal: Blood (2015)